Veracyte Announces Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Veracyte (VCYT) Tops Q2 EPS by 8c, Beats on Revenue; Offers FY24 Revenue Guidance
August 6, 2024 4:20 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of $0.07, $0.08 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $100.27 million.
GUIDANCE:
Veracyte sees FY2024 revenue of $432-438 million, versus the consensus of $406.3... More
